# AI Breakthrough: Predicting Alzheimer’s Decline Newsy: Alzheimer’s News Weekly Published: 2025-12-29T13:30:00.331Z Source: https://newsyai.com/edition/fd25e26f-0b6b-4837-b8ab-f369769d68a1 Archive: https://newsyai.com/newsy/2e52bc28-656d-42e4-981f-28a7be9142df.md --- # Alzheimer’s Treatment Briefing Coverage period: December 23–29, 2025 Note: It was a quiet holiday week for headline clinical trial readouts. Still, a few fresh, practical advances landed that could meaningfully improve how we pick, time, and deliver treatments. ## Top stories (ranked) 1) AI tool predicts who will decline using just one spinal‑fluid test - Overview - A new research preprint (Dec 22) introduces PROGRESS, an AI system that can estimate a person’s risk and timing of decline from a single baseline spinal‑fluid (CSF) sample, without needing months of prior clinic data. It provides both a “when” (time to progress from mild impairment to dementia) and a “how fast” forecast, and it reports uncertainty, so doctors can discuss trade‑offs honestly. The model was trained and tested on data from more than 3,000 people across 43 U.S. Alzheimer’s centers. ([arxiv.org](https://arxiv.org/abs/2512.19099?utm_source=openai)) - Why this matters - Disease‑slowing drugs work best when started early, but today many patients wait months for repeat testing before decisions are made. A reliable “day‑one” forecast could speed up access to the right therapy, help clinics prioritize those most likely to benefit now, and avoid overtreatment in those expected to stay stable longer. ([arxiv.org](https://arxiv.org/abs/2512.19099?utm_source=openai)) - Sources - https://arxiv.org/abs/2512.19099 ([arxiv.org](https://arxiv.org/abs/2512.19099?utm_source=openai)) 2) Making “tau PET” from a standard MRI could open precision treatment to far more people - Overview - A second preprint (Dec 17) shows that a deep‑learning method can create a high‑quality “synthetic tau PET” image from a regular MRI. Tau PET scans show the spread of tangles that track symptoms, but they’re expensive and not widely available. In testing on Alzheimer’s Disease Neuroimaging Initiative data, the synthetic images preserved the key disease signals closely enough to support similar diagnostic performance to real tau PET in a classifier. ([arxiv.org](https://arxiv.org/abs/2512.15947?utm_source=openai)) - Why this matters - Many treatment decisions (for example, enrolling in tau‑targeting add‑on trials) depend on knowing where tau is in the brain. If clinics can approximate tau PET from a routine MRI, more patients could be triaged to the right drug or study without long waits or high costs. It won’t replace PET yet, but it could be a powerful screening step. ([arxiv.org](https://arxiv.org/abs/2512.15947?utm_source=openai)) - Sources - https://arxiv.org/abs/2512.15947 ([arxiv.org](https://arxiv.org/abs/2512.15947?utm_source=openai)) 3) Medicare signals major coverage shift for weight‑loss drugs; indirect implications for Alzheimer’s care - Overview - On Dec 24, the U.S. Centers for Medicare & Medicaid Services unveiled a new, voluntary model to expand coverage of GLP‑1 medicines (like Wegovy and Zepbound) across Medicaid and Medicare Part D, with standardized terms and capped out‑of‑pocket costs targeted for future rollout. While GLP‑1s failed this year as a direct Alzheimer’s treatment, they do improve weight, diabetes, and blood‑pressure control—conditions that worsen brain health. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/us-health-agency-expand-access-glp-1-weight-loss-drugs-2025-12-23/?utm_source=openai)) - Why this matters - Better access to GLP‑1s could lower vascular risk factors that accelerate memory decline and complicate use of Alzheimer’s drugs (for example, uncontrolled hypertension increases risk of brain microbleeds). This policy shift won’t treat Alzheimer’s itself, but it could make the brain a “safer place” for disease‑slowing therapies to work. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/us-health-agency-expand-access-glp-1-weight-loss-drugs-2025-12-23/?utm_source=openai)) - Sources - https://www.reuters.com/business/healthcare-pharmaceuticals/us-health-agency-expand-access-glp-1-weight-loss-drugs-2025-12-23/ ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/us-health-agency-expand-access-glp-1-weight-loss-drugs-2025-12-23/?utm_source=openai)) 4) Quick reference: where antibody treatments stand after the fall conference season - Overview - Although not new this week, late‑December practice planning often hinges on the most recent fall data: - Lecanemab (Leqembi) subcutaneous autoinjector is FDA‑approved for weekly maintenance at home after completing the initial IV phase; U.S. launch began Oct 6, 2025. ([investors.biogen.com](https://investors.biogen.com/news-releases/news-release-details/fda-approves-leqembir-iqliktm-lecanemab-irmb-subcutaneous?utm_source=openai)) - New CTAD analyses suggest starting earlier and staying on therapy could translate into several extra years before reaching moderate disease in people with low amyloid at baseline. ([prnewswire.com](https://www.prnewswire.com/news-releases/new-leqembi-data-presented-at-ctad-2025-suggests-potential-to-delay-disease-progression-by-up-to-8-3-years-with-continued-treatment-302632744.html?utm_source=openai)) - Why this matters - As clinics plan January scheduling, these updates affect infusion capacity, MRI monitoring plans, and who is most likely to benefit (earlier starters, confirmed by biomarkers). Consider using this to guide discussions on timing and home‑injection maintenance. ([prnewswire.com](https://www.prnewswire.com/news-releases/new-leqembi-data-presented-at-ctad-2025-suggests-potential-to-delay-disease-progression-by-up-to-8-3-years-with-continued-treatment-302632744.html?utm_source=openai)) - Sources - https://investors.biogen.com/news-releases/news-release-details/fda-approves-leqembir-iqliktm-lecanemab-irmb-subcutaneous ([investors.biogen.com](https://investors.biogen.com/news-releases/news-release-details/fda-approves-leqembir-iqliktm-lecanemab-irmb-subcutaneous?utm_source=openai)) - https://www.ajmc.com/view/fda-approves-once-weekly-dosing-for-lecanemab-irmb-to-treat-early-alzheimer-disease ([ajmc.com](https://www.ajmc.com/view/fda-approves-once-weekly-dosing-for-lecanemab-irmb-to-treat-early-alzheimer-disease?utm_source=openai)) - https://www.prnewswire.com/news-releases/new-leqembi-data-presented-at-ctad-2025-suggests-potential-to-delay-disease-progression-by-up-to-8-3-years-with-continued-treatment-302632744.html ([prnewswire.com](https://www.prnewswire.com/news-releases/new-leqembi-data-presented-at-ctad-2025-suggests-potential-to-delay-disease-progression-by-up-to-8-3-years-with-continued-treatment-302632744.html?utm_source=openai)) - https://www.globenewswire.com/news-release/2025/12/3/3199431/0/en/Eisai-Presents-New-Data-on-the-Continued-and-Expanding-Benefit-of-LEQEMBI-lecanemab-irmb-Maintenance-Treatment-in-Early-Alzheimer-s-Disease-at-the-Clinical-Trials-on-Alzheimer-s-Di.html ([globenewswire.com](https://www.globenewswire.com/news-release/2025/12/3/3199431/0/en/Eisai-Presents-New-Data-on-the-Continued-and-Expanding-Benefit-of-LEQEMBI-lecanemab-irmb-Maintenance-Treatment-in-Early-Alzheimer-s-Disease-at-the-Clinical-Trials-on-Alzheimer-s-Di.html?utm_source=openai)) ## What this means for care right now - Use fast, data‑light prognostics to speed decisions: - Ask research‑active clinics if they can pilot “first‑visit” risk tools like PROGRESS to prioritize earlier treatment starts where appropriate. ([arxiv.org](https://arxiv.org/abs/2512.19099?utm_source=openai)) - Expand access to tau‑informed care without delays: - Where tau PET is scarce, consider MRI‑based AI screening as it matures, to identify who most needs PET or who may qualify for tau‑targeted add‑ons. ([arxiv.org](https://arxiv.org/abs/2512.15947?utm_source=openai)) - Leverage cardiometabolic care as an Alzheimer’s “force multiplier”: - GLP‑1 coverage expansion won’t treat Alzheimer’s directly, but better control of weight, diabetes, and blood pressure can reduce complications and make treatment pathways smoother. Coordinate with primary care. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/us-health-agency-expand-access-glp-1-weight-loss-drugs-2025-12-23/?utm_source=openai)) —— If you want, I can track only truly “new this week” items going forward and skip sections when there’s no meaningful change.